Avenir Global appoints Miranda Dini global healthcare lead

Avenir Global has appointed  Miranda Dini as global healthcare lead, adding to her ongoing leadership of the communications firm’s Axon business in Europe.

Her new expanded role will involve spearheading cross-firm initiatives to strengthen Avenir’s global healthcare business.

This has been expanded in recent years with the acquisitions of Cherry and Hanover, adding to its Madano, National, Padilla and Shift companies, and currently accounts for more than 30% of the group’s business.

Ralph Sutton, Avenir Global’s international managing partner, said: “We work with healthcare clients in every one of our brands, providing a wide range of services, including insights, strategic planning, public relations, medical communications, clinical trial services, creative, branding and market access.

“Miranda has a deep understanding of the expertise within our firm and a proven track record for driving growth and collaboration.  She is the ideal person to help orchestrate our network resources to deliver great results for our clients.”

Dini has been leading the Axon business in Europe since 2012, during which time she has overseen a tripling in size of its operations.

She said: “What I love about our firm is that we consciously collaborate, as we know we bring different strengths and expertise to the table.  By putting our clients first, we don’t get caught up in bureaucracy or agency politics.

“We focus on helping our clients effectively communicate the value of what they’re trying to achieve, by seamlessly bringing together deep experience, dynamic insights and diverse viewpoints to deliver breakthrough creative solutions.”

A Montreal-based holding and management company, Avenir Global has 1,000 staff and offices in 24 locations across Canada, the US, Europe and the Middle East and is itself owned by Res Publica Consulting Group.

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.